Cytoreductive surgery and adjuvant immunotherapy: a new management paradigm for metastatic melanoma

Although patients with metastatic disease are usually not offered surgery as part of their comprehensive treatment plan, the authors suggest that surgical reduction of the tumor burden may enhance the host immune response and create a favorable setting for the use of active specific immunotherapy.

Saved in:
Bibliographic Details
Published in:CA: a cancer journal for clinicians 1999-03, Vol.49 (2), p.101-116
Main Authors: Morton, D. L, Ollila, D. W, Hsueh, E. C, Essner, R, Gupta, R. K
Format: Article
Language:English
Subjects:
Cancer
Combined Modality Therapy
Drug therapy
Humans
Immunology
Immunotherapy
Melanoma - immunology
Melanoma - secondary
Melanoma - surgery
Melanoma - therapy
Surgery
Tumors
Citations: Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although patients with metastatic disease are usually not offered surgery as part of their comprehensive treatment plan, the authors suggest that surgical reduction of the tumor burden may enhance the host immune response and create a favorable setting for the use of active specific immunotherapy.
ISSN:0007-9235
1542-4863
DOI:10.3322/canjclin.49.2.101